Abstract:Small-cell lung cancer (SCLC) accounts for 13–15% of all new lung cancer cases in the US. The tumor has a tendency to disseminate early resulting in 80–85% of patients being diagnosed with extensive disease (ES-SCLC). Chemotherapy has provided SCLC patients considerable survival benefits over the past three decades. Nonetheless, most patients relapse and rarely survive beyond 2 years. Despite consistent overall response rates of ≥50%, until recently, median survival times and 2-year survivals only ranged between 7–10 months and 10–20%, respectively. Several chemotherapy agents possess activity against SCLC, both, as single agents and in combinations but etoposide-platinum emerged as the preferred first line regimen. Upon relapse, many patients remain candidates for additional therapy. However, the sensitivity of relapsed SCLC to further therapies is markedly reduced and dependent upon the level and duration of response to the initial treatment (platinum-sensitive vs. resistant relapse). Multiple factors suggest a therapeutic role for immunotherapy in SCLC:(1) SCLC has been associated with immune-mediated paraneoplastic processes (cerebellar degeneration, limbic encephalitis, and Lambert–Eaton syndrome) and patients presenting with these paraneoplastic syndromes have shown more favorable outcomes, suggesting an underlying immune response mechanism.(2) Comprehensive genomic profiling of SCLC indicates that the majority lack functional p53 (90%) and Rb1 (65%). These universal genetic aberrations facilitate poor genomic stability, thus perpetuating the generation of tumor associated antigens, amenable to targeting with immunotherapy.(3) SCLC has one of the highest mutational loads, likely a reflection of the myriad of insults inflicted by smoking-related carcinogens. The relationship between tumor mutational load and response to immune checkpoint inhibitors has been established in multiple solid tumors, including preliminary results in relapsed SCLC.In this manuscript, we review the early (some failed and discontinued, some partly successful, and still ongoing) attempts to incorporate immunotherapy (particularly vaccine based approaches) to the treatment of SCLC, and the latest attempts (mostly incorporating the use of checkpoint inhibitors), including those with favorable but preliminary results (CheckMate 032, Keynote 028 and 158), and those with more definitive positive (iMpower 133 and CASPIAN) and negative (CheckMate 331 and 451) results.

Update of Research on Drug Resistance in Small Cell Lung Cancer Chemotherapy

Research on Chemoresistance of Small Cell Lung Cancer

Small Cell Lung Cancer—An Update on Chemotherapy Resistance

Current Status and Progress of the Treatment of Limited-Disease Small Cell Lung Cancer

Strategies to Target Chemoradiotherapy Resistance in Small Cell Lung Cancer

The research advances of drug therapy of small cell lung cancer

New insights into small‐cell lung cancer development and therapy

Small Cell Lung Cancer: Will Recent Progress Lead to Improved Outcomes?

Research Progress of Anti-Angiogenic Drugs in First-Line Treatment of Small Cell Lung Cancer

Update 2021: Management of Small Cell Lung Cancer

Opportunities and obstacles of targeted therapy and immunotherapy in small cell lung cancer

Research progress in the treatment of small cell lung cancer

Current Small Cell Lung Cancer Treatment In China

Small cell lung cancer: emerging subtypes, signaling pathways, and therapeutic vulnerabilities

Update on the Biology, Management, and Treatment of Small Cell Lung Cancer (SCLC)

Emerging Strategies for the Treatment of Small Cell Lung Cancer: A Review

[Recent Advances and Future Strategies for Small Cell Lung Cancer].

Immunotherapy As a Treatment for Small Cell Lung Cancer: a Case Report and Brief Review

Current and future therapeutic approaches for the treatment of small cell lung cancer

Advances in antiangiogenic treatment of small-cell lung cancer

Current Status and Progress of CAR-T Cell Therapy in the Treatment of Small Cell Lung Cancer